Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 5/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9425356 | 0.77 | NQO1 (0.56) | MEN1KMT2AMAPTNPC1LMNA | |
| SCHEMBL4707838 | 0.74 | NQO1 (0.47) | SMN1; SMN2MAPTRAB9AMAOBLMNA | |
| SCHEMBL4800898 | 0.73 | NPC1 (0.33) | MAPTNPC1RAB9A | |
| SCHEMBL1224848 | 0.73 | APP (0.47) | MAPTMAOB | |
| SCHEMBL14938867 | 0.72 | NR4A1 (0.42) | SMN1; SMN2MEN1KMT2AMAPTNPC1 | |
| SCHEMBL29492090 | 0.72 | NR4A1 (0.42) | SMN1; SMN2MEN1KMT2AMAPTNPC1 | |
| SCHEMBL1547536 | 0.71 | MAOB (0.60) | KMT2AMAPTRAB9AMAOBLMNA | |
| SCHEMBL3823883 | 0.71 | MAOB (0.62) | SMN1; SMN2MAPTRAB9AMAOBLMNA | |
| SCHEMBL1134723 | 0.70 | CA1 (0.53) | SMN1; SMN2MEN1KMT2AMAPTNPC1 | |
| SCHEMBL30250475 | 0.70 | CA1 (0.53) | SMN1; SMN2MEN1KMT2AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| EP-2061789-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008032858-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-20 | — | — | WO | disclosed |
| US-5401768-A | Prostaglandin derivative, antiulcer, hypotensive, anticoagulant | TORAY INDUSTRIES, INC. (JP) | 1995-03-28 | — | — | US | disclosed |
| EP-0365678-B1 | 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF | TORAY INDUSTRIES (JP) | 1994-01-05 | — | — | EP | disclosed |
| EP-0389162-B1 | 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES (JP) | 1993-12-08 | — | — | EP | disclosed |
| US-5086071-A | Improved chemical stability and ppotent in vivo | TORAY INDUSTRIES, INC. (JP) | 1992-02-04 | — | — | US | disclosed |
| EP-0232776-B1 | 2,5,6,7-TETRANOR-4,8-INTER-M-PHENYLENE PGI2 DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1990-10-24 | — | — | EP | disclosed |
| EP-0389162-A1 | 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1990-09-26 | — | — | EP | disclosed |
| EP-0365678-A1 | 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1990-05-02 | — | — | EP | disclosed |
| US-4775692-A | ANTILIPEMIC, ANTICOAGULANT, HYPOTENSIVE, ANTISECRETORY AND ANTIULCER AGENT | TORAY INDUSTRIES, INC. (JP) | 1988-10-04 | — | — | US | disclosed |
| EP-0232776-A2 | 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | SMN1; SMN2 3564/4885MEN1 4525/4885KMT2A 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.